TY - JOUR
T1 - Aggressive Posterior Retinopathy of Prematurity
T2 - Clinical and Quantitative Imaging Features in a Large North American Cohort
AU - Bellsmith, Kellyn N.
AU - Brown, James
AU - Kim, Sang Jin
AU - Goldstein, Isaac H.
AU - Coyner, Aaron
AU - Ostmo, Susan
AU - Gupta, Kishan
AU - Chan, R. V.Paul
AU - Kalpathy-Cramer, Jayashree
AU - Chiang, Michael F.
AU - Campbell, J. Peter
N1 - Funding Information:
Supported by the National Institutes of Health, Bethesda, Maryland (grant nos.: R01EY19474, K12EY027720, T15LM007088, and P30EY10572); the National Science Foundation, Arlington, Virginia (grant nos.: 1622542 and SCH-1622679); and Research to Prevent Blindness, Inc., New York, New York (unrestricted departmental funding and Career Development Award [J.P.C.]). None of the funding agencies had any role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
Publisher Copyright:
© 2020 American Academy of Ophthalmology
PY - 2020/8
Y1 - 2020/8
N2 - Purpose: Aggressive posterior retinopathy of prematurity (AP-ROP) is a vision-threatening disease with a significant rate of progression to retinal detachment. The purpose of this study was to characterize AP-ROP quantitatively by demographics, rate of disease progression, and a deep learning-based vascular severity score. Design: Retrospective analysis. Participants: The Imaging and Informatics in ROP cohort from 8 North American centers, consisting of 947 patients and 5945 clinical eye examinations with fundus images, was used. Pretreatment eyes were categorized by disease severity: none, mild, type 2 or pre-plus, treatment-requiring (TR) without AP-ROP, TR with AP-ROP. Analyses compared TR with AP-ROP and TR without AP-ROP to investigate differences between AP-ROP and other TR disease. Methods: A reference standard diagnosis was generated for each eye examination using previously published methods combining 3 independent image-based gradings and 1 ophthalmoscopic grading. All fundus images were analyzed using a previously published deep learning system and were assigned a score from 1 through 9. Main Outcome Measures: Birth weight, gestational age, postmenstrual age, and vascular severity score. Results: Infants who demonstrated AP-ROP were more premature by birth weight (617 g vs. 679 g; P = 0.01) and gestational age (24.3 weeks vs. 25.0 weeks; P < 0.01) and reached peak severity at an earlier postmenstrual age (34.7 weeks vs. 36.9 weeks; P < 0.001) compared with infants with TR without AP-ROP. The mean vascular severity score was greatest in TR with AP-ROP infants compared with TR without AP-ROP infants (8.79 vs. 7.19; P < 0.001). Analyzing the severity score over time, the rate of progression was fastest in infants with AP-ROP (P < 0.002 at 30–32 weeks). Conclusions: Premature infants in North America with AP-ROP are born younger and demonstrate disease earlier than infants with less severe ROP. Disease severity is quantifiable with a deep learning-based score, which correlates with clinically identified categories of disease, including AP-ROP. The rate of progression to peak disease is greatest in eyes that demonstrate AP-ROP compared with other treatment-requiring eyes. Analysis of quantitative characteristics of AP-ROP may help improve diagnosis and treatment of an aggressive, vision-threatening form of ROP.
AB - Purpose: Aggressive posterior retinopathy of prematurity (AP-ROP) is a vision-threatening disease with a significant rate of progression to retinal detachment. The purpose of this study was to characterize AP-ROP quantitatively by demographics, rate of disease progression, and a deep learning-based vascular severity score. Design: Retrospective analysis. Participants: The Imaging and Informatics in ROP cohort from 8 North American centers, consisting of 947 patients and 5945 clinical eye examinations with fundus images, was used. Pretreatment eyes were categorized by disease severity: none, mild, type 2 or pre-plus, treatment-requiring (TR) without AP-ROP, TR with AP-ROP. Analyses compared TR with AP-ROP and TR without AP-ROP to investigate differences between AP-ROP and other TR disease. Methods: A reference standard diagnosis was generated for each eye examination using previously published methods combining 3 independent image-based gradings and 1 ophthalmoscopic grading. All fundus images were analyzed using a previously published deep learning system and were assigned a score from 1 through 9. Main Outcome Measures: Birth weight, gestational age, postmenstrual age, and vascular severity score. Results: Infants who demonstrated AP-ROP were more premature by birth weight (617 g vs. 679 g; P = 0.01) and gestational age (24.3 weeks vs. 25.0 weeks; P < 0.01) and reached peak severity at an earlier postmenstrual age (34.7 weeks vs. 36.9 weeks; P < 0.001) compared with infants with TR without AP-ROP. The mean vascular severity score was greatest in TR with AP-ROP infants compared with TR without AP-ROP infants (8.79 vs. 7.19; P < 0.001). Analyzing the severity score over time, the rate of progression was fastest in infants with AP-ROP (P < 0.002 at 30–32 weeks). Conclusions: Premature infants in North America with AP-ROP are born younger and demonstrate disease earlier than infants with less severe ROP. Disease severity is quantifiable with a deep learning-based score, which correlates with clinically identified categories of disease, including AP-ROP. The rate of progression to peak disease is greatest in eyes that demonstrate AP-ROP compared with other treatment-requiring eyes. Analysis of quantitative characteristics of AP-ROP may help improve diagnosis and treatment of an aggressive, vision-threatening form of ROP.
UR - http://www.scopus.com/inward/record.url?scp=85081894261&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081894261&partnerID=8YFLogxK
U2 - 10.1016/j.ophtha.2020.01.052
DO - 10.1016/j.ophtha.2020.01.052
M3 - Article
C2 - 32197913
AN - SCOPUS:85081894261
SN - 0161-6420
VL - 127
SP - 1105
EP - 1112
JO - Ophthalmology
JF - Ophthalmology
IS - 8
ER -